Cargando…
Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
INTRODUCTION: This study aimed to estimate risks of cardiovascular and cerebrovascular events in patients treated with lisdexamfetamine dimesylate (LDX) compared with patients previously treated with other attention-deficit/hyperactivity disorder (ADHD) medications (amphetamine, dexamphetamine, meth...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588134/ https://www.ncbi.nlm.nih.gov/pubmed/36028603 http://dx.doi.org/10.1007/s40120-022-00396-y |
_version_ | 1784814060738445312 |
---|---|
author | Forns, Joan Dudukina, Elena Hägg, David Szentkúti, Péter Gembert, Karin Plana, Estel Gilsenan, Alicia Horváth-Puhó, Erzsébet Ehrenstein, Vera Reutfors, Johan Rebordosa, Cristina |
author_facet | Forns, Joan Dudukina, Elena Hägg, David Szentkúti, Péter Gembert, Karin Plana, Estel Gilsenan, Alicia Horváth-Puhó, Erzsébet Ehrenstein, Vera Reutfors, Johan Rebordosa, Cristina |
author_sort | Forns, Joan |
collection | PubMed |
description | INTRODUCTION: This study aimed to estimate risks of cardiovascular and cerebrovascular events in patients treated with lisdexamfetamine dimesylate (LDX) compared with patients previously treated with other attention-deficit/hyperactivity disorder (ADHD) medications (amphetamine, dexamphetamine, methylphenidate or atomoxetine). METHODS: This population-based cohort study used data from Danish and Swedish medical and administrative national registers. The LDX cohort included adult patients initiating LDX with at least 12 months’ data preceding first LDX dispensing (index date). A random sample of patients treated with at least one non-LDX ADHD medication in the 6–24 months (but not less than 6 months) before index date (previous-users cohort) were matched to LDX users on age, sex, region and calendar year. The primary outcome, a composite of major adverse cardiovascular and cerebrovascular events (MACE), included first hospitalisation for acute myocardial infarction or stroke and out-of-hospital coronary heart disease or cerebrovascular disease death. Incidence rates (IRs) and IR ratios (IRRs) with 95% confidence intervals (CIs) of MACE were estimated using Poisson regression. RESULTS: From Denmark/Sweden, 5516/40,163 LDX users and 27,494/200,389 previous users were included. In Denmark, IRs of MACE/1000 person-years (95% CI) were similar for LDX (1.63 [0.85–3.14]) and previous users (1.61 [1.28–2.01]). In Sweden, IRs (95% CI) were 1.40 (1.09–1.79) in LDX users and 1.17 (1.00–1.38) in previous users. Adjusted MACE IRRs (95% CI) for LDX versus previous use were 1.01 (0.48–2.13) in Denmark, 1.13 (0.75–1.71) in Sweden, and 1.10 (0.77–1.58) in the pooled analysis. CONCLUSION: Our findings suggest little to no increased risk of cardiovascular and cerebrovascular events in patients treated with LDX compared with patients previously treated with other ADHD medications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-022-00396-y. |
format | Online Article Text |
id | pubmed-9588134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-95881342022-11-29 Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study Forns, Joan Dudukina, Elena Hägg, David Szentkúti, Péter Gembert, Karin Plana, Estel Gilsenan, Alicia Horváth-Puhó, Erzsébet Ehrenstein, Vera Reutfors, Johan Rebordosa, Cristina Neurol Ther Original Research INTRODUCTION: This study aimed to estimate risks of cardiovascular and cerebrovascular events in patients treated with lisdexamfetamine dimesylate (LDX) compared with patients previously treated with other attention-deficit/hyperactivity disorder (ADHD) medications (amphetamine, dexamphetamine, methylphenidate or atomoxetine). METHODS: This population-based cohort study used data from Danish and Swedish medical and administrative national registers. The LDX cohort included adult patients initiating LDX with at least 12 months’ data preceding first LDX dispensing (index date). A random sample of patients treated with at least one non-LDX ADHD medication in the 6–24 months (but not less than 6 months) before index date (previous-users cohort) were matched to LDX users on age, sex, region and calendar year. The primary outcome, a composite of major adverse cardiovascular and cerebrovascular events (MACE), included first hospitalisation for acute myocardial infarction or stroke and out-of-hospital coronary heart disease or cerebrovascular disease death. Incidence rates (IRs) and IR ratios (IRRs) with 95% confidence intervals (CIs) of MACE were estimated using Poisson regression. RESULTS: From Denmark/Sweden, 5516/40,163 LDX users and 27,494/200,389 previous users were included. In Denmark, IRs of MACE/1000 person-years (95% CI) were similar for LDX (1.63 [0.85–3.14]) and previous users (1.61 [1.28–2.01]). In Sweden, IRs (95% CI) were 1.40 (1.09–1.79) in LDX users and 1.17 (1.00–1.38) in previous users. Adjusted MACE IRRs (95% CI) for LDX versus previous use were 1.01 (0.48–2.13) in Denmark, 1.13 (0.75–1.71) in Sweden, and 1.10 (0.77–1.58) in the pooled analysis. CONCLUSION: Our findings suggest little to no increased risk of cardiovascular and cerebrovascular events in patients treated with LDX compared with patients previously treated with other ADHD medications. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-022-00396-y. Springer Healthcare 2022-08-26 /pmc/articles/PMC9588134/ /pubmed/36028603 http://dx.doi.org/10.1007/s40120-022-00396-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Forns, Joan Dudukina, Elena Hägg, David Szentkúti, Péter Gembert, Karin Plana, Estel Gilsenan, Alicia Horváth-Puhó, Erzsébet Ehrenstein, Vera Reutfors, Johan Rebordosa, Cristina Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study |
title | Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study |
title_full | Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study |
title_fullStr | Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study |
title_full_unstemmed | Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study |
title_short | Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study |
title_sort | risk of major cardiovascular and cerebrovascular events in users of lisdexamfetamine and other medications for attention-deficit/hyperactivity disorder in denmark and sweden: a population-based cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588134/ https://www.ncbi.nlm.nih.gov/pubmed/36028603 http://dx.doi.org/10.1007/s40120-022-00396-y |
work_keys_str_mv | AT fornsjoan riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT dudukinaelena riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT haggdavid riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT szentkutipeter riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT gembertkarin riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT planaestel riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT gilsenanalicia riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT horvathpuhoerzsebet riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT ehrensteinvera riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT reutforsjohan riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy AT rebordosacristina riskofmajorcardiovascularandcerebrovasculareventsinusersoflisdexamfetamineandothermedicationsforattentiondeficithyperactivitydisorderindenmarkandswedenapopulationbasedcohortstudy |